The Improvement Effect of Magnolia officinalis Oil Extract on Non-alcoholic Fatty Liver Disease and Its Mechanism of Regulating Inflammatory Pathways and Oxidative Stress in HepG2 cells
TOTAL VIEWS: 172
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder characterized by lipid accumulation and hepatic inflammation. Magnolia officinalis, a traditional herbal medicine, has shown potential therapeutic effects in various metabolic conditions. However, its mechanisms of action in NAFLD remain unclear. Methods: HepG2 cells were treated with oleic and palmitic acid to establish an NAFLD model and then exposed to water, ethanol, or ethyl acetate extracts of Cortex Magnoliae Officinalis at varying concentrations for 6 or 24 hours. The SIRT1/AMPK pathway was investigated using shRNA knockdown and plasmid overexpression, with transfection efficiency confirmed via RT-qPCR and fluorescence microscopy. Gene expression, cell viability, and cytokine levels were analyzed using RT-qPCR, CCK-8 assay, and ELISA, respectively, with statistical analyses to evaluate significance. Results: Our findings suggest that Magnolia officinalis ethanol extracts activate the SIRT1/AMPK pathway, leading to improved lipid metabolism and reduced oxidative stress and hepatic inflammation. These effects appear to modulate pro-inflammatory cytokines and alleviate metabolic dysregulation associated with NAFLD. Conclusions: Magnolia officinalis extracts exhibit promising therapeutic potential in NAFLD management by targeting the SIRT1/AMPK pathway and reducing inflammation. Further in vivo studies are required to confirm these findings, investigate long-term safety and bioavailability, and explore synergistic effects with other therapeutic compounds. This research bridges traditional natural medicine with advanced scientific methods, providing novel insights into NAFLD treatment.
References
[1] Ji L, Li Q, He Y, Zhang X, Zhou Z, Gao Y, et al. Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: A promising drug Potentilla discolor Bunge. Acta Pharmaceutica Sinica B. 2022;12(9):3529-47.
[2] Tilg H, Targher G. NAFLD-related mortality: simple hepatic steatosis is not as ‘benign’ as thought. Gut. 2021;70(7):1212-3.
[3] Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577-86.
[4] Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysi-ology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63.
[5] Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686-90.
[6] Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76:99-128.
[7] Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med. 2009;87:679-95.
[8] Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther. 2017;34:1291-326.
[9] Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res. 2009;48(1):1-26.
[10] Shao M, Ye Z, Qin Y, Wu T. Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease. Exp Ther Med. 2020;20(5):1-1.
[11] Deng Y, Tang K, Chen R, Nie H, Liang S, Zhang J, et al. Berberine attenuates hepatic oxidative stress in rats with non-alcoholic fatty liver disease via the Nrf2/ARE signalling pathway. Exp Ther Med. 2019;17(3):2091-8.
[12] Schug TT, Li X. Sirtuin 1 in lipid metabolism and obesity. Ann Med. 2011;43(3):198-211.
[13] Guo X, Yin X, Liu Z, Wang J. Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci. 2022;23(24):15489.
[14] Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res. 2013;47(11):869-80.
[15] Yahoo N, Dudek M, Knolle P, Heikenwälder M. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.
[16] Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation. 2019;103(1):e1-e13.
[17] Scorletti E, Carr RM. A new perspective on NAFLD: Focusing on lipid droplets. J Hepatol. 2022;76(4):934-45.
[18] Wen W, Wu P, Zhang Y, Chen Z, Sun J, Chen H. Comprehensive analysis of NAFLD and the therapeutic target identified. Front Cell Dev Biol. 2021;9:704704.
[19] Michelotti A, de Scordilli M, Palmero L, Guardascione M, Masala M, Roncato R, et al. NAFLD-related hepatocarcinoma: the malignant side of metabolic syndrome. Cells. 2021;10(8):2034.
[20] Rinaldi L, Pafundi PC, Galiero R, Caturano A, Morone MV, Silvestri C, et al. Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review. Antioxidants. 2021;10(2):270.
[21] Zarghamravanbakhsh P, Frenkel M, Poretsky L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metab Open. 2021;12:100149.
[22] Hughey CC, Puchalska P, Crawford PA. Integrating the contributions of mitochondrial oxidative metabolism to lipotoxicity and inflammation in NAFLD pathogenesis. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(11):159209.
[23] Naik A, Belič A, Zanger UM, Rozman D. Molecular interactions between NAFLD and xenobiotic metabolism. Front Genet. 2013;4:2.
[24] Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(39):14205.
[25] Klisic A, Kavaric N, Ninic A, Kotur-Stevuljevic J. Oxidative stress and cardiometabolic biomarkers in patients with non-alcoholic fatty liver disease. Sci Rep. 2021;11(1):18455.
[26] Liu F, Zhu S, Xiong Z. Anti-anxiety and antidepressant properties of bioactive neolignans derived from Magnolia officinalis.
[27] Rodriguez-Mateos A, Feliciano RP, Boeres A, Weber T, Dos Santos CN, Ventura MR, et al. Cranberry (poly) phenol metabolites correlate with improvements in vascular function: A double-blind, randomized, controlled, dose-response, crossover study. Mol Nutr Food Res. 2016;60(10):2130-40.
[28] Luo H, Wu H, Yu X, Zhang X, Lu Y, Fan J, et al. A review of the phytochemistry and pharmacological activities of Magnoliae officinalis cortex. J Ethnopharmacol. 2019;236:412-42.
[29] Khan A, Ross HM, Parra NS, Chen SL, Chauhan K, Wang M, et al. Risk prevention and health promotion for non-alcoholic fatty liver diseases (NAFLD). Livers. 2022;2(4):264-82.
[30] Liang Z, Chen X, Shi J, Hu H, Xue Y, Ung COL. Efficacy and safety of traditional Chinese medicines for non-alcoholic fatty liver disease: a systematic literature review of randomized controlled trials. Chin Med. 2021;16:1-38.
[31] Seo MS, Hong SW, Yeon SH, Kim YM, Um KA, Kim JH, et al. Magnolia officinalis attenuates free fatty acid-induced lipogenesis via AMPK phosphorylation in hepatocytes. J Ethnopharmacol. 2014;157:140-8.
[32] Tian Y, Feng H, Han L, Wu L, Lv H, Shen B, et al. Magnolol alleviates inflammatory responses and lipid accumulation by AMP-activated protein kinase-dependent peroxisome proliferator-activated receptor α activation. Front Immunol. 2018;9:147.
[33] Xie NA, Hu C, Guo A, Liang H, Du P, Yin G. Metabolic regulation of magnolol on the nuclear receptor, liver X receptor. Exp Ther Med. 2015;9(5):1827-30.
[34] Nassir F, Rector RS, Hammoud GM, Ibdah JA. Pathogenesis and prevention of hepatic steatosis. 2015 Mar.
[35] Anggreini P, Kuncoro H, Sumiwi SA, Levita J. Role of the AMPK/SIRT1 pathway in non-alcoholic fatty liver disease. Mol Med Rep. 2023;27(2):1-11.
How to cite this paper
The Improvement Effect of Magnolia officinalis Oil Extract on Non-alcoholic Fatty Liver Disease and Its Mechanism of Regulating Inflammatory Pathways and Oxidative Stress in HepG2 cells
How to cite this paper: Zeming Li, Kai Jia, Jun Zhou. (2024) The Improvement Effect of Magnolia officinalis Oil Extract on Non-alcoholic Fatty Liver Disease and Its Mechanism of Regulating Inflammatory Pathways and Oxidative Stress in HepG2 cells. Advance in Biological Research, 5(2), 65-74.
DOI: http://dx.doi.org/10.26855/abr.2024.12.004
More Articles
- The Improvement Effect of Magnolia officinalis Oil Extract on Non-alcoholic Fatty Liver Disease and Its Mechanism of Regulating Inflammatory Pathways and Oxidative Stress in HepG2 cells
- Single-omics Approaches to Improve Abiotic Stress Tolerance in Faba Bean: A Review
- Applications of Bioinformatics in Biology and Medicine
- Management of Kitchen Waste Material Through the Use of Black Soldier Fly Larvae (Hermetia illucens) for Sustainable Waste Management and Availability of Feed for Livestock
- Vegetation Diversity in Native Mixed-Korean Pine Forests
- Distribution and Status of Coffee Berry Disease in Western Oromia, Ethiopia